Lazard Asset Management
JUNO

Lazard Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Lazard Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-81,260
Closed -$4.24M – 1236
2014
Q4 		$4.24M Buy
+81,260
New +$3.64M 0.01% 562

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Lazard Asset Management's JUNO Position: Q1 2015 in Review

Lazard Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2015, closing a stake of 81,260 shares — an estimated $4.24M sold.

Lazard Asset Management first reported a position in JUNO in Q4 2014 and held it in 1 quarter. The position peaked at $4.24M in Q4 2014. 120 funds tracked by Wall St. Rank hold JUNO as of Q1 2015.

  • Lazard Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Lazard Asset Management sold 81,260 Juno Therapeutics, Inc. shares in Q1 2015, an estimated $4.24M.
  • Lazard Asset Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • Lazard Asset Management's Juno Therapeutics, Inc. position peaked at $4.24M in Q4 2014.
  • 120 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2015.

Based on Lazard Asset Management's 13F filing for Q1 2015, filed 15 May 2015.